NasdaqGS:RVMDBiotechs
A Look At Revolution Medicines (RVMD) Valuation After Daraxonrasib Expanded Access Approval
Revolution Medicines (RVMD) is back in focus after the FDA cleared expanded access to its investigational drug daraxonrasib for certain metastatic pancreatic cancer patients, following Phase 3 data showing improvements in overall survival and progression-free survival.
See our latest analysis for Revolution Medicines.
The stock’s recent move appears closely linked to the daraxonrasib news flow, with a 1 day share price return of 6.04% and a 30 day share price return of 49.21% contributing to...